Frontline ALK+ NSCLC management

preview_player
Показать описание
Tom Newsom-Davis, BSc, MBBS, PhD, FRCP, Chelsea and Westminster Hospital NHS Foundation Trust, London, UK, discusses the management of ALK+ non-small cell lung cancer (NSCLC) with a focus on brain metastases. This interview took place at the 18th British Thoracic Oncology Group (BTOG) 2020 congress held in Dublin, UK.
  1. VJOncology
  2. Speaker: Tom Newsom-Davis
  3. Event: BTOG 2020
  4. Format: Interview
  5. Subject: Lung Cancer
  6. Subject: Non-Small Cell Lung Cancer
Рекомендации по теме
Management of frontline 0:03:04

Management of frontline ALK+ NSCLC: brigatinib vs. alectinib

Dr. Xia on 0:01:17

Dr. Xia on the Frontline Treatment Landscape of ALK-Positive NSCLC

Dr. Liu on 0:01:22

Dr. Liu on Navigating the Frontline Treatment of ALK+ NSCLC

Dr. West on 0:00:55

Dr. West on FDA Approval of Frontline Alectinib in ALK+ NSCLC

ALEX Trial: Frontline 0:08:15

ALEX Trial: Frontline Therapy for ALK-Rearranged NSCLC

DEBATE: ALK positive 0:13:28

DEBATE: ALK positive NSCLC - Front line therapy - Crizotinib

FDA Approval: Frontline 0:05:31

FDA Approval: Frontline Ceritinib for ALK+ NSCLC

Progression in ALK+ 0:06:51

Progression in ALK+ NSCLC After Frontline Therapy

Exploring Treatment Options 0:00:58

Exploring Treatment Options for Patients with ALK-Mutated Lung Cancer

Dr. Velcheti on 0:01:42

Dr. Velcheti on Potential of Alectinib in Frontline ALK-Positive NSCLC

DEBATE: ALK positive 0:11:38

DEBATE: ALK positive NSCLC - Front line therapy - Ceritinib

Frontline Targeted Therapy 0:02:41

Frontline Targeted Therapy in ALK+ NSCLC

Targeting ALK - 0:45:52

Targeting ALK - From Discovery to Frontline Treatment

Frontline ALK, EGFR 0:05:54

Frontline ALK, EGFR Inhibition in Non-Small Cell Lung Cancer

Frontline Treatments in 0:02:04

Frontline Treatments in ALK-Rearranged NSCLC

Management of ALK-Positive, 0:06:23

Management of ALK-Positive, NSCLC

Frontline Systemic Therapy 0:01:45

Frontline Systemic Therapy for ALK+ mNSCLC

Frontline Treatment of 0:03:30

Frontline Treatment of Advanced NSCLC

Dr. Massarelli on 0:01:07

Dr. Massarelli on First-Line ALK + NSCLC Treatment

Immunotherapy in Non-Small 0:32:12

Immunotherapy in Non-Small Cell Lung Cancer (NSCLC): Front Line Therapy

Alectinib in ALK-Mutated 0:03:59

Alectinib in ALK-Mutated NSCLC

CROWN: lorlatinib in 0:02:37

CROWN: lorlatinib in treatment-naïve patients with ALK-positive advanced NSCLC

Available Therapies for 0:03:13

Available Therapies for ALK-Rearranged NSCLC

Dr. Neal Debates 0:01:27

Dr. Neal Debates Whether Alectinib Will Become the Standard Frontline Thera for ALK+ NSCLC